• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Crit Care . Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19

tetano

Editor, Senior Moderator
Crit Care


. 2020 Jul 13;24(1):422.
doi: 10.1186/s13054-020-03120-0.
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19


Wentao Ni[SUP] 1 [/SUP], Xiuwen Yang[SUP] 2 [/SUP], Deqing Yang[SUP] 3 [/SUP], Jing Bao[SUP] 1 [/SUP], Ran Li[SUP] 1 [/SUP], Yongjiu Xiao[SUP] 4 [/SUP], Chang Hou[SUP] 5 [/SUP], Haibin Wang[SUP] 6 [/SUP], Jie Liu[SUP] 7 [/SUP], Donghong Yang[SUP] 1 [/SUP], Yu Xu[SUP] 8 [/SUP], Zhaolong Cao[SUP] 9 [/SUP], Zhancheng Gao[SUP] 10 [/SUP]



Affiliations

Abstract

An outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that started in Wuhan, China, at the end of 2019 has become a global pandemic. Both SARS-CoV-2 and SARS-CoV enter host cells via the angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in various human organs. We have reviewed previously published studies on SARS and recent studies on SARS-CoV-2 infection, named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), confirming that many other organs besides the lungs are vulnerable to the virus. ACE2 catalyzes angiotensin II conversion to angiotensin-(1-7), and the ACE2/angiotensin-(1-7)/MAS axis counteracts the negative effects of the renin-angiotensin system (RAS), which plays important roles in maintaining the physiological and pathophysiological balance of the body. In addition to the direct viral effects and inflammatory and immune factors associated with COVID-19 pathogenesis, ACE2 downregulation and the imbalance between the RAS and ACE2/angiotensin-(1-7)/MAS after infection may also contribute to multiple organ injury in COVID-19. The SARS-CoV-2 spike glycoprotein, which binds to ACE2, is a potential target for developing specific drugs, antibodies, and vaccines. Restoring the balance between the RAS and ACE2/angiotensin-(1-7)/MAS may help attenuate organ injuries. SARS-CoV-2 enters lung cells via the ACE2 receptor. The cell-free and macrophage-phagocytosed virus can spread to other organs and infect ACE2-expressing cells at local sites, causing multi-organ injury.

Keywords: Angiotensin-converting enzyme 2; COVID-19; Multi-organ injury; SARS-CoV-2.
 
Back
Top Bottom